In the SURPASS-5 phase III study, subcutaneous tirzepatide was added to titrated insulin glargine, and produced statistically significant improvements in glycemic control among patients with type II diabetes mellitus, as opposed to a placebo. Here, INS is linked to type 2 diabetes mellitus.